Since January is National Birth Defects Prevention Month, it represents an opportune time to inform pregnant patients and their families about some lesser-known risks for birth defects that may help to improve neonatal outcomes.
This slideshow shows drug information for Twirla. Click here for the complete Twirla monograph.
Similar in-person rules for other medications have been suspended during the pandemic
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Prior to pregnancy, her viral load had been undetectable for more than 2 years.
Merzee contains 24 active capsules containing 1mg of norethindrone acetate and 20mcg of ethinyl estradiol and 4 capsules containing 75mg of ferrous fumarate.
This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.
Oteseconazole is a novel oral inhibitor of fungal CYP51.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI <30kg/m2 for whom a combined hormonal contraceptive is appropriate.
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
